@article{fdfd798b0dc34993a5a42c8c4e2fa042,
title = "Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions",
abstract = "Azacitidine and decitabine are hypomethylating agents that have dose-dependent epigenetic and cytotoxic effects and are widely used in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In this review, we discuss the path to regulatory approval of azacitidine and decitabine, highlighting the substantial efforts that have been made to optimize the dosing schedule and administration of these drugs, including the development of new, oral formulations of both agents. We also review novel combination strategies that are being investigated in ongoing clinical trials for patients with MDS and AML, as well as efforts to expand the current indications of these agents.",
author = "Short, {Nicholas J.} and Hagop Kantarjian",
note = "Funding Information: Nicholas J. Short is supported by the K12 Paul Calabresi Clinical Oncology Scholar Award and the American Society of Hematology Junior Faculty Scholar Award in Clinical Research. Funding Information: Nicholas J. Short has served as consultant for Takeda Oncology, Pfizer, and Jazz Pharmaceuticals, reports receiving research grants from Takeda Oncology, Astellas Pharma Inc., Stemline, and Xencor, and has received honoraria from Amgen and Astellas Pharma Inc. Hagop Kantarjian has received research grants from AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi‐Sankyo, Immunogen, Jazz Pharma, Novartis, Pfizer, Actinium, and Takeda. Publisher Copyright: {\textcopyright} 2022 Wiley Periodicals LLC.",
year = "2022",
month = dec,
doi = "10.1002/ajh.26667",
language = "English (US)",
volume = "97",
pages = "1616--1626",
journal = "American journal of hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "12",
}